GBA Presents: THE GREEN MARKET

Good AM so JEALOUS VAN how did you change that little pic to the one of the painting! It looks amazing. It's called the clan of something... I can't remember, I was really taken with it... It's old as hell and may of come from some ancient book. I nailed that upstate auction! They didn't know what hit them... I was coming off being abused in Chicago with bidders w / very deep pockets. Came in late as a sniper...

Roblox price target lowered to $110 from $134 at Stifel 08:17 RBLX Stifel analyst Drew Crum lowered the firm's price target on Roblox to $110 from $134 and keeps a Buy rating on the shares as he has trimmed his Q4 estimates to reflect more conservatism with December assumptions ahead of the company being expected to report Q4 results in late February. He now forecasts Q4 bookings at $743M, up 16% on both a year-over-year and quarter-over-quarter basis, versus $787M previously.
 
stonedinvestor said:
Good AM so JEALOUS VAN how did you change that little pic to the one of the painting! It looks amazing. It's called the clan of something... I can't remember, I was really taken with it... It's old as hell and may of come from some ancient book. I nailed that upstate auction! They didn't know what hit them... I was coming off being abused in Chicago with bidders w / very deep pockets. Came in late as a sniper...
More...
I really liked it lol.
 
Another test of SNAP today.

Snap price target lowered to $55 from $65 at Jefferies 07:50 SNAP

Infosys added to Best Ideas List at Wedbush 07:49 INFY

Safe-T initiated with a Buy at Dawson James 07:41 SFET

International Paper price target raised to $54 from $49 at Truist 07:31 IP Truist analyst Michael Roxland raised the firm's price target on International Paper to $54 from $49 but keeps a Hold rating on the shares. The analyst states that he has become more constructive on containerboard over the near-term, citing higher prices, better demand, and more manageable supply increases but also notes that International Paper is contending with company specific issues and self-help initiatives, which could mute the benefits of higher prices.

Packaging Corp. upgraded to Buy from Hold at Truist 07:28 PKG

PKG IS A BUY FOLKS!<---------
 
Van I want you to know something and I swear I swear I did not know you were short AFRM when I contacted Nikko. I really thought only about myself. I am so sorry.

Affirm selloff brings 'compelling buying opportunity,' says SMBC Nikko 07:18 AFRM SMBC Nikko analyst Andrew…
 
Seres Therapeutics to hold a virtual investor event 08:25 MCRB Virtual Inve

Badger Meter upgraded to Buy from Hold at Maxim 07:59 BMI Maxim analyst Tate Sullivan upgraded Badger Meter to Buy from Hold with a $125 price target.

Oh No Van... Van, Van, Van no... Man. I told you! NEVER EVER SHORT one of my longs....
There was a guy here at ET that did that years ago and he blew himself up. It was on a boat, he blew it sky high.... His name was John something.

Ayyyyyyyyyyyy.

DA Davidson upgrades Affirm to Buy, sees 'material upside' heading into results » 07:47 AFRM, AMZN
 
Alumina upgraded to Overweight from Neutral at JPMorgan 07:24 AWCMY JPMorgan

Vivid Seats initiated with an Outperform at Credit Suisse 06:20 SEAT Credit Suisse analyst Stephen Ju initiated coverage of Vivid Seats with an Outperform rating and $16 price target. The analyst notes that during 2021, Vivid Seats launched its new web v2.0 and mobile v3.0 experiences, as well as its updated loyalty program, which collectively should drive higher repeat order rates and output to higher customer LTV and higher long-term adjusted EBITDA margins. Ju also sees potential for faster-than-expected new user growth, and optionality for additional revenue streams to emerge from Betcha Sports.

Azek upgraded to Overweight from Equal Weight at Stephens 06:15 AZEK

Indaptus Therapeutics assumed with a Buy at H.C. Wainwright 06:13 INDP H.C. Wainwright analyst Raghuram Selvaraju assumed coverage of Indaptus Therapeutics with a Buy rating and $15 price target. The company's Decoy platform is based on the hypothesis that efficient activation of both innate and adaptive immune cells and associated anti-tumor and anti-viral immune responses will require a multi-targeted package of immune system activating signals that can be administered safely intravenously, Selvaraju tells investors in a research note.
 
WISeKey says experiencing unprecedented demand, record backlog 05:18 WKEY Carlos Moreira,

I have no idea what they are saying it's in French. But this little company has been profiled by us no less than five times! And granted it hasn't moved very much BUT it also has NOT gone down very much... a $3 name to WATCH!

 
You must log in or register to reply here.
Back
Top